Subject: The Brits don't understand.......
Date: Tue, 7 Apr 1998 152917 -0500 (CDT)
From: "Roy L. Beavers" <rbeavers@llion.org>
To: emfguru@hotmail.com
--------------------------------------------------
Hey everybody!!!
In the following news item out of the U.K., it is clear to me
that the Brits simply don't understand the Yanks -- or U.S.
science!!! They think that the U.S. scientists at the National
Cancer Institute (NCI) are (supposed to be) behaving like scientists.....
Hell no!!! Science is not what NCI is all about ... making money is!!!
(For their pharmacological "industry" partners that is.....)
You can be sure ... the Yanks are going to get there 'first' to control
things like patents, trade-names, the market, etc..... They're not in the
business of science. They are in the money business!!! NCI = one of
America's RICH health bureaucracies.....
And ... as readers of these pages know ... NCI's claims about Tamoxifen
are _suspect_ ... to the extent that they have ***consciously*** ignored
the effect upon the 'Tamoxifen action' that can be caused by exposure to
EMF...... EMF being one of the most prevalent exposure contaminants in
the world environment today........
Now we know why NCI played so fast and loose with the facts about the
LINET study. With this announcement about Tamoxifen as a "preventer"
of breast cancer about to be revealed, they simply could not afford
to have the questions about EMF "blocking the Tamoxifen effect" being
raised ... which might contradict their smug "Tamoxifen will prevent
breast cancer" thesis.....
Question: Is not the same Dr. Fischer (sp?) -- who yesterday
lauded the Tamoxifen announcement -- also the same Dr. Fischer (sp?)
who loudly announced to the whole world (at the time of the Linet study)
that there was "no EMF problem, and it was time to stop spending money on
EMF research????"
Hey British science!!!! When you come West across that big ocean ...
you arrive in a world where science is not about "science" ... or even
the public's health!!! It's about money!!!!!.......
Cheerio...... (Everybody ... pass this one to your media friends!!!
Somebody can get a story here.....)
Roy Beavers (EMFguru)
rbeavers@llion.org..............http://www.feb.se/EMF-L/EMF-L.html
................................It is better to light a single candle ...
than to curse the darkness...............................................
DO YOU KNOW OF ANYONE ELSE WHO SHOULD BE ON THIS LIST???
_________________________________________________________________
_________________________________________________________________
01:39 PM ET 04/07/98
UK doctors criticize U.S. handling of cancer study
By Patricia Reaney
LONDON (Reuters) - British experts accused American
researchers Tuesday of jumping the gun by releasing data showing
the drug tamoxifen can cut by 45 percent the incidence of breast
cancer in high-risk women.
The British scientists said although the news was
encouraging, the U.S. National Cancer Institute (NCI) had been
short-sighted in going public so early.
It had set back the long-term goal of finding out if the
drug can stop women from dying of the disease, they told a news
conference. ``There has been significant over-reaction from the
United States,'' said Dr Trevor Powles, of the Royal Marsden
Hospital in London.
``Even though there has been a reduction in breast cancer
cases, we are still only talking about a handful of women.''
The U.S. researchers effectively halted a study into the
effects of tamoxifen a year early Monday when they announced
that women who had been taking a dummy pill as part of the trial
would be given the chance to take tamoxifen instead.
Results showed there were 85 cases of invasive breast cancer
among the more than 6,600 women who had taken the drug, compared
to 154 cases in an equal number of women on dummy pills.
``This is the first time in history that we have evidence
that breast cancer can not only be treated but also be
prevented,'' said Dr Bernard Fisher, scientific director of the
study.
British doctors from the Cancer Research Campaign and the
Imperial Cancer Research Fund insisted it was not a question of
sour grapes, and denied that they were reacting in a typically
conservative British manner.
``This is just one clinical trial that may have been stopped
prematurely,'' said Professor Tony Howell. ``We still have no
significant results about the long-term results (of tamoxifen)
as a preventive agent.''
Powles said the International Breast Cancer Intervention
Study (IBIS) of tamoxifen, involving 7,000 healthy but high-risk
women in Britain, Australia and New Zealand, would continue. But
the participants would be told the results of the U.S. research.
A similar trial is also underway in Italy.
Powles and other British cancer experts were caught unawares
by the style and scale of the U.S. announcement, which hailed
the findings as a major breakthrough.
They criticized the bravura manner in which the results were
released to the press, and questioned whether there was enough
evidence to publicize the results. It would be difficult in the
``fullness of time'' to know what the American study had proved,
they said.
``This is not the way one goes about promoting scientific
results,'' said Professor Michael Baum, a British authority on
breast cancer.
``I don't see why it had to be so expeditiously done,''
added Powles.
Tamoxifen is not a new drug. It has been used to treat early
and advanced stages of breast cancer since the 1970s. Clinical
trials have shown it reduces recurrence and outbreaks of cancer
in the opposite breast.
The drug, which is given in pill form, interferes with the
activity of the female hormone estrogen.
Some breast cancer cells are estrogen sensitive, so that the
hormone binds to the cells and helps the cancer spread.
Tamoxifen prevents that binding of estrogen and stops the cancer
cells from growing.
It has also been shown to benefit women whose tumors are not
estrogen sensitive. But the drug, produced by Zeneca
Pharmaceutical of Wilmington, Del., a subsidiary of the British
drugs company Zeneca Group Plc, is not without side effects.
The most common side effect is hot flashes, similar to those
during menopause. It can also increase a woman's risk of
developing uterine cancer, pulmonary embolism (blood clots in
the lung) and deep vein thrombosis, where blood clots form
within vessels or in the heart.
^REUTERS@
Archive provided courtesy of WaveGuide, http://www.wave-guide.org
Reprinted with permission of Roy Beavers, http://www.feb.se/EMF-L/EMF-L.html